{"id":"W2885588864","doi":"10.1016/s0140-6736(18)31773-2","title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":804,"is_retracted":false,"has_abstract":false,"ca_institutions":"York University; LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk","keywords":"Medicine; Semaglutide; Liraglutide; Placebo; Clinical endpoint; Dose-ranging study; Weight loss; Randomized controlled trial; Intention-to-treat analysis; Internal medicine; Body mass index; Obesity; Type 2 diabetes; Diabetes mellitus; Double blind; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02126388715541555,"score_gpt":0.284934066006599,"score_spread":0.2636701788511835,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}